CoChat

mRNA structure regulates protein expression through changes in functional half-life

Open access

Published version of a preprint

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Abstract

Messenger RNAs (mRNAs) encode information in both their primary sequence and their higher order structure. The independent contributions of factors like codon usage and secondary structure to regulating protein expression are difficult to establish as they are often highly correlated in endogenous sequences. Here, we used 2 approaches, global inclusion of modified nucleotides and rational sequence design of exogenously delivered constructs, to understand the role of mRNA secondary structure independent from codon usage. Unexpectedly, highly expressed mRNAs contained a highly structured coding sequence (CDS). Modified nucleotides that stabilize mRNA secondary structure enabled high expression across a wide variety of primary sequences. Using a set of eGFP mRNAs with independently altered codon usage and CDS structure, we find that the structure of the CDS regulates protein expression through changes in functional mRNA half-life (i.e., mRNA being actively translated). This work highlights an underappreciated role of mRNA secondary structure in the regulation of mRNA stability.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1908052116

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Inclusion of modified nucleotides in mRNA alters eGFP and hEPO expression. (A) Chemical structure of uridine and 4 modified nucleosides: (Ψ, m1Ψ, mo5U, and m5C. (B) Fluorescence intensity (normalized intensity units, y axis) of HeLa cells following transfection with lipofectamine alone (−) or 4 different eGFP sequence variants (G1–G4, x axis) containing uridine (gray), m1Ψ (orange), Ψ (yellow), m5C/Ψ (lavender), or mo5U (dark purple). (C, Top) Schematic of the hEpo mRNA sequence variants. Eight hEpo sequences combined 1 of 2 “head” regions (dark gray box, HA or HB) encoding the first 30 amino acids (90 nucleotides) and 1 of 4 “body” regions (light gray box, E1–E4) encoding the remainder of the hEpo CDS. (C, Bottom) Levels of secreted hEpo protein measured by ELISA (ng/mL, y axis) following transfection of cells with 8 sequence variants (described in B above, x axis) plus 1 “codon optimized” variant (ECO) (44) containing uridine (gray bars), m1Ψ (orange), or mo5U (dark purple). (D) Serum concentrations of hEpo protein measured by ELISA (ng/mL, y axis) in BALB-c mice (5 per group) following IV injection of LNP-formulated mRNA of 6 sequence variants (described in B above, x axis) plus 1 codon optimized variant (ECO) (44) containing m1Ψ (orange) or mo5U (dark purple). Individual animals (dots) with mean and SE (black lines).
Fig. 1. Inclusion of modified nucleotides in mRNA alters eGFP and hEPO expression. (A) Chemical structure of uridine and 4 modified nucleosides: (Ψ, m1Ψ, mo5U, and m5C. (B) Fluorescence intensity (normalized intensity units, y axis) of HeLa cells following transfection with lipofectamine alone (−) or 4 different eGFP sequence variants (G1–G4, x axis) containing uridine (gray), m1Ψ (orange), Ψ (yellow), m5C/Ψ (lavender), or mo5U (dark purple). (C, Top) Schematic of the hEpo mRNA sequence variants. Eight hEpo sequences combined 1 of 2 “head” regions (dark gray box, HA or HB) encoding the first 30 amino acids (90 nucleotides) and 1 of 4 “body” regions (light gray box, E1–E4) encoding the remainder of the hEpo CDS. (C, Bottom) Levels of secreted hEpo protein measured by ELISA (ng/mL, y axis) following transfection of cells with 8 sequence variants (described in B above, x axis) plus 1 “codon optimized” variant (ECO) (44) containing uridine (gray bars), m1Ψ (orange), or mo5U (dark purple). (D) Serum concentrations of hEpo protein measured by ELISA (ng/mL, y axis) in BALB-c mice (5 per group) following IV injection of LNP-formulated mRNA of 6 sequence variants (described in B above, x axis) plus 1 codon optimized variant (ECO) (44) containing m1Ψ (orange) or mo5U (dark purple). Individual animals (dots) with mean and SE (black lines).CC BY · PubMed Central
Fig. 2. Inclusion of modified nucleotides in mRNA alters Luc expression. (A, Left) Expression in HeLa cells (relative light units [RLU], y axis) for 39 firefly Luciferase sequence variants (L1–L39, x axis) containing uridine (gray, Top), m1Ψ (orange, Middle), or mo5U (dark purple, Bottom). (A, Right) Distribution of expression levels (RLU, y axis) for variants (black dots) containing uridine (gray), m1Ψ (orange), and mo5U (dark purple) as a violin plot. (B) Expression in HeLa cells (RLU, y axis) of 39 firefly Luciferase variants grouped by the codon used (x axis) for all instances of serine (Top), phenylalanine (Middle), and threonine (Bottom) in mRNAs containing uridine (Left), m1Ψ (Middle), or mo5U (Right). Codons are shown in order of frequency of occurrence in the human transcriptome. Individual values (dots) are the same as in A with mean and SEs (black lines). Significant differences by 2-way ANOVA comparisons are indicated by lines above, and P values are noted by asterisks (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, and ****P ≤ 0.0001). (C) Total luminescence of in vivo firefly Luciferase expression (RLU, y axis) in CD-1 mice (5 per group) following IV injection of 0.15 mg/kg LNP-formulated mRNA for 10 sequence variants (x axis) containing m1Ψ (Top) or mo5U (Bottom). Individual animals (dots) with median.
Fig. 2. Inclusion of modified nucleotides in mRNA alters Luc expression. (A, Left) Expression in HeLa cells (relative light units [RLU], y axis) for 39 firefly Luciferase sequence variants (L1–L39, x axis) containing uridine (gray, Top), m1Ψ (orange, Middle), or mo5U (dark purple, Bottom). (A, Right) Distribution of expression levels (RLU, y axis) for variants (black dots) containing uridine (gray), m1Ψ (orange), and mo5U (dark purple) as a violin plot. (B) Expression in HeLa cells (RLU, y axis) of 39 firefly Luciferase variants grouped by the codon used (x axis) for all instances of serine (Top), phenylalanine (Middle), and threonine (Bottom) in mRNAs containing uridine (Left), m1Ψ (Middle), or mo5U (Right). Codons are shown in order of frequency of occurrence in the human transcriptome. Individual values (dots) are the same as in A with mean and SEs (black lines). Significant differences by 2-way ANOVA comparisons are indicated by lines above, and P values are noted by asterisks (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, and ****P ≤ 0.0001). (C) Total luminescence of in vivo firefly Luciferase expression (RLU, y axis) in CD-1 mice (5 per group) following IV injection of 0.15 mg/kg LNP-formulated mRNA for 10 sequence variants (x axis) containing m1Ψ (Top) or mo5U (Bottom). Individual animals (dots) with median.CC BY · PubMed Central
Fig. 3. Modified nucleotides induce global structural changes in mRNA. (A) Optical melting profiles of firefly Luciferase sequence variants (L18 Top, L15 Middle, and L32 Bottom) containing uridine (gray), m1Ψ (orange), or mo5U (dark purple) showing the change in UV absorbance at 260 nm (y axis) as a function of temperature (x axis). (B) Nearest-neighbor thermodynamic parameters for Watson–Crick base pairs (x axis) containing uridine (gray circles, values from ref. 20), Ψ (yellow diamonds), m1Ψ (orange squares), or mo5U (dark purple triangles). The modified nucleotides in each nearest neighbor are highlighted in red.
Fig. 3. Modified nucleotides induce global structural changes in mRNA. (A) Optical melting profiles of firefly Luciferase sequence variants (L18 Top, L15 Middle, and L32 Bottom) containing uridine (gray), m1Ψ (orange), or mo5U (dark purple) showing the change in UV absorbance at 260 nm (y axis) as a function of temperature (x axis). (B) Nearest-neighbor thermodynamic parameters for Watson–Crick base pairs (x axis) containing uridine (gray circles, values from ref. 20), Ψ (yellow diamonds), m1Ψ (orange squares), or mo5U (dark purple triangles). The modified nucleotides in each nearest neighbor are highlighted in red.CC BY · PubMed Central
Fig. 4. SHAPE data reveal a bipartite relationship between mRNA structure and protein expression. (A) Median SHAPE reactivity values (33-nt sliding window) for firefly Luc sequence variants L18 (Top), L8 (Middle), and L32 (Bottom), containing m1Ψ (orange, Top) or mo5U (purple, Bottom) shown as a heatmap: highly reactive (red), moderately reactive (gray), and lowly reactive (blue). Total luminescence values in mice from Fig. 2C are shown at Right. (B) Expression in HeLa cells (y axis, from Fig. 2A) for 39 firefly Luciferase variants (dots) containing uridine (dark gray, Top) or m1Ψ (orange, Bottom) versus median windowed SHAPE reactivity value (x axis) in 2 33-nt windows centered at the indicated positions. (C) Pearson correlations for SHAPE vs. protein expression in HeLa cells (y axis) across nucleotide positions (x axis) for 39 firefly Luciferase sequence variants containing U (dark gray, Top), m1Ψ (orange, Middle), or mo5U (dark purple, Bottom). The light gray boxes show the empirical 95% confidence interval at each position.
Fig. 4. SHAPE data reveal a bipartite relationship between mRNA structure and protein expression. (A) Median SHAPE reactivity values (33-nt sliding window) for firefly Luc sequence variants L18 (Top), L8 (Middle), and L32 (Bottom), containing m1Ψ (orange, Top) or mo5U (purple, Bottom) shown as a heatmap: highly reactive (red), moderately reactive (gray), and lowly reactive (blue). Total luminescence values in mice from Fig. 2C are shown at Right. (B) Expression in HeLa cells (y axis, from Fig. 2A) for 39 firefly Luciferase variants (dots) containing uridine (dark gray, Top) or m1Ψ (orange, Bottom) versus median windowed SHAPE reactivity value (x axis) in 2 33-nt windows centered at the indicated positions. (C) Pearson correlations for SHAPE vs. protein expression in HeLa cells (y axis) across nucleotide positions (x axis) for 39 firefly Luciferase sequence variants containing U (dark gray, Top), m1Ψ (orange, Middle), or mo5U (dark purple, Bottom). The light gray boxes show the empirical 95% confidence interval at each position.CC BY · PubMed Central
Fig. 5. Half-life of computationally designed eGFP-degron mRNAs is determined by codon usage and mRNA structure. (A) Codon optimality (relative synonymous codon usage, y axis) versus secondary structure (energy of the predicted MFE structure, x axis) for sets of 150,000 generated eGFP sequence variants generated using codons chosen randomly (red), weighted in proportion to the human genome(blue), and using our algorithm (gray). Colored boxes show regions from which sequences were selected for further testing. (B) Total integrated eGFP fluorescence measured every 2 h for 86 h in HeLa cells (relative fluorescence unit [RFU], y axis) for 6 sets of 5 mRNAs containing m1Ψ (dots, with median as black line) with differing degrees of codon optimality and/or secondary structure (x axis, as in A). Significant differences by 2-way ANOVA comparisons are indicated by lines above, and P values are noted by asterisks (**P ≤ 0.01). (C) Model of eGFP expression kinetics. Simulated curves based on equations for changes in levels of mRNA (mRNA, orange), immature nonfluorescent protein (inactive protein, gray), and mature fluorescent protein (fluor, green) over time using exponential decay rates for mRNA (λRNA) and eGFP protein (λFluor), and rates of translation (kTrans) and protein maturation (kMAT). mRNA half-lives (t1/2 RNA) were calculated from the observed mRNA decay rates. (D) eGFP-degron fluorescence in HeLa cells (RFU, y axis) versus time (x axis) as measured experimentally (solid colored lines as in A) and fitted according to the model in C (dashed black lines) for representative sequence variants with differing degrees of codon optimality and/or secondary structure (as in A). Translation rate constants (kTrans) and mRNA half-lives (t1/2 RNA) as derived from the model described in C are shown. (E) Total eGFP-degron fluorescence in HeLa cells (RFU, y axis) versus the modeled rate constants for translation (kTrans, Left) or mRNA functional half-life (λRNA, Right) for 20 sequence variants containing m1Ψ as in D. Linear regression (black line) and Pearson correlation are shown. (F) Modeled functional mRNA half-lives (λRNA, y axis) for 4 sets of 5 eGFP-degron sequence variants with differing degrees of codon optimality and/or secondary structure (x axis, as in A and B).
Fig. 5. Half-life of computationally designed eGFP-degron mRNAs is determined by codon usage and mRNA structure. (A) Codon optimality (relative synonymous codon usage, y axis) versus secondary structure (energy of the predicted MFE structure, x axis) for sets of 150,000 generated eGFP sequence variants generated using codons chosen randomly (red), weighted in proportion to the human genome(blue), and using our algorithm (gray). Colored boxes show regions from which sequences were selected for further testing. (B) Total integrated eGFP fluorescence measured every 2 h for 86 h in HeLa cells (relative fluorescence unit [RFU], y axis) for 6 sets of 5 mRNAs containing m1Ψ (dots, with median as black line) with differing degrees of codon optimality and/or secondary structure (x axis, as in A). Significant differences by 2-way ANOVA comparisons are indicated by lines above, and P values are noted by asterisks (**P ≤ 0.01). (C) Model of eGFP expression kinetics. Simulated curves based on equations for changes in levels of mRNA (mRNA, orange), immature nonfluorescent protein (inactive protein, gray), and mature fluorescent protein (fluor, green) over time using exponential decay rates for mRNA (λRNA) and eGFP protein (λFluor), and rates of translation (kTrans) and protein maturation (kMAT). mRNA half-lives (t1/2 RNA) were calculated from the observed mRNA decay rates. (D) eGFP-degron fluorescence in HeLa cells (RFU, y axis) versus time (x axis) as measured experimentally (solid colored lines as in A) and fitted according to the model in C (dashed black lines) for representative sequence variants with differing degrees of codon optimality and/or secondary structure (as in A). Translation rate constants (kTrans) and mRNA half-lives (t1/2 RNA) as derived from the model described in C are shown. (E) Total eGFP-degron fluorescence in HeLa cells (RFU, y axis) versus the modeled rate constants for translation (kTrans, Left) or mRNA functional half-life (λRNA, Right) for 20 sequence variants containing m1Ψ as in D. Linear regression (black line) and Pearson correlation are shown. (F) Modeled functional mRNA half-lives (λRNA, y axis) for 4 sets of 5 eGFP-degron sequence variants with differing degrees of codon optimality and/or secondary structure (x axis, as in A and B).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

13 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 57 references

Cited by

See all 569

Metadata

Authors
Mauger, D. M., Cabral, B. J., Presnyak, V., Su, S. V., Reid, D. W., Goodman, B., Link, K., Khatwani, N., Reynders, J., Moore, M. J., & McFadyen, I. J.
Affiliations
Platform Research, Moderna, Inc., Cambridge, MA 02139
Corresponding author
Moore, Melissa J.
Venue
Proceedings of the National Academy of Sciences
Published
2019-11-11
Volume
116
Issue
48
Pages
24075-24083
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2983889514
Cited by
555
References
56
Citations by year
2026: 76 · 2025: 105 · 2024: 104 · 2023: 73 · 2022: 98 · 2021: 71 · 2020: 26 · 2019: 2
FWCI
16.54
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Moderna
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
mRNA secondary structure, mRNA stability, mRNA half-life, codon usage, protein expression regulation, modified nucleotides, mRNA translation
MeSH terms
Half-Life, HeLa Cells, Humans, Nucleic Acid Conformation, Proteins, RNA, Messenger, Protein Biosynthesis, RNA Stability

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: mRNA structure regulates protein expression through changes in functional half-life. https://app.cochat.ai/papers/10.1073/pnas.1908052116
The paper
Mauger, D. M., Cabral, B. J., Presnyak, V., Su, S. V., Reid, D. W., Goodman, B., Link, K., Khatwani, N., Reynders, J., Moore, M. J., & McFadyen, I. J. (2019). mRNA structure regulates protein expression through changes in functional half-life. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1908052116

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.